典型文献
Peripheral blood indices to predict PFS/OS with anlotinib as a subsequent treatment in advanced small-cell lung cancer
文献摘要：
Objective: In the phase Ⅱ ALTER-1202 (NCT03059797) trial, anlotinib significantly improved progression-free survival (PFS) and overall survival (OS) in patients with advanced small-cell lung cancer (SCLC) who underwent at least 2 previous chemotherapy cycles, when compared with a placebo group. To identify potential factors for predicting efficacy and prognosis with anlotinib treatment, we analyzed hematological indices at baseline and adverse events (AEs) over the course of anlotinib treatment. Methods: Data were collected from March 2017 to April 2019 from a randomized, double-blind, placebo-controlled, multicenter, phase Ⅱ trial of anlotinib. Eligible patients were randomly assigned 2:1 to receive anlotinib or placebo until disease progression, intolerable toxicity, or withdrawal of consent. The patients received anlotinib (12 mg) or an analogue capsule (placebo) orally once daily for 14 days every 3 weeks. The hematological indices at baseline and AEs that occurred in the initial 2 treatment cycles were recorded. The Kaplan-Meier test and Cox regression model were used to assess survival differences. Results: A total of 82 patients (81 patients with complete data) were randomly assigned to receive anlotinib, with 38 receiving a placebo as a control. Multivariate analysis indicated that an elevated neutrophil to lymphocyte ratio > 7.75 and lactate dehydrogenase > 254.65 U/L at baseline were independent risk factors for PFS; basal elevated aspartate aminotransferase > 26.75 U/L, neuron specific enolase > 18.64 ng/mL, and fibrinogen > 4.645 g/L were independent risk factors for OS. During treatment, elevated γ glutamyltransferase and hypophosphatemia were independent predictors for a poor PFS, and elevated γ-glutamyl transferase and hypercholesterolemia were independent factors for OS. Conclusions: Our study preliminarily defined potential factors that affected the PFS and OS at baseline and during anlotinib treatment in patients with advanced SCLC. Our findings provide a basis for screening the dominant population and for dynamic efficacy monitoring with anlotinib therapy.
文献关键词：
中图分类号：
作者姓名：
Cuicui Zhang;Jing Wang;Xinyue Wang;Zhaoting Meng;Ying Cheng;Kai Li
作者机构：
Department of Thoracic Oncology Tianjin Medical University Cancer Institute and Hospital,National Clinical Research Center for Cancer,Key Laboratory of Cancer Prevention and Therapy,Tianjin,Tianjin's Clinical Research Center for Cancer,Tianjin 300060,China;Jilin Cancer Hospital,Changchun 130021,China
文献出处：
引用格式：
[1]Cuicui Zhang;Jing Wang;Xinyue Wang;Zhaoting Meng;Ying Cheng;Kai Li-.Peripheral blood indices to predict PFS/OS with anlotinib as a subsequent treatment in advanced small-cell lung cancer)[J].癌症生物学与医学（英文版）,2022(08):1249-1258
A类：
ALTER,NCT03059797
B类：
Peripheral,blood,indices,PFS,OS,anlotinib,subsequent,treatment,advanced,small,cell,lung,cancer,Objective,In,phase,trial,significantly,improved,progression,free,survival,overall,patients,SCLC,who,underwent,least,previous,chemotherapy,cycles,when,compared,placebo,group,To,identify,potential,factors,predicting,efficacy,prognosis,analyzed,hematological,baseline,adverse,events,AEs,course,Methods,Data,were,collected,from,March,April,randomized,double,blind,controlled,multicenter,Eligible,randomly,assigned,until,disease,intolerable,toxicity,withdrawal,consent,received,analogue,capsule,orally,once,daily,days,every,weeks,that,occurred,initial,recorded,Kaplan,Meier,test,Cox,regression,model,used,assess,differences,Results,total,complete,data,receiving,Multivariate,analysis,indicated,elevated,neutrophil,lymphocyte,ratio,lactate,dehydrogenase,independent,risk,basal,aspartate,aminotransferase,neuron,specific,enolase,fibrinogen,During,glutamyltransferase,hypophosphatemia,predictors,poor,hypercholesterolemia,Conclusions,Our,study,preliminarily,defined,affected,during,findings,provide,basis,screening,dominant,population,dynamic,monitoring
AB值：
0.514702
相似文献
机标中图分类号，由域田数据科技根据网络公开资料自动分析生成，仅供学习研究参考。
